SAN FRANCISCO (AP) — Federal prosecutors in San Francisco say Genentech and OSI Pharmaceuticals have agreed to pay $67 million to settle allegations they misled doctors about the effectiveness of a cancer drug.

The U.S. attorney’s office in Northern California announced the settlement on Monday.

READ MORE: Home Alone: Helping Pandemic Pets Cope When Their Owners Return To Work

It came in a whistleblower lawsuit over the drug Tarceva.

The pharmaceutical companies were accused of making misleading statements about Tarceva between January 2006 and December 2011.

READ MORE: Neighbors Creating Holiday Magic On Candy Cane Lane In Pleasanton Since 1953

According to a lawsuit, there was little evidence the drug was effective to treat certain lung cancer patients unless they never smoked or had a particular mutation.

Neither company acknowledged wrongdoing.

Genentech spokeswoman Holli Kolkey said the company believes its promotional communications for Tarceva were legal.

MORE NEWS: As Oakland Lawmakers Prepare To Vote To Increase Police Staffing New Report Questions Need

Astellas Pharma said the alleged misconduct preceded its acquisition of OSI, and it decided to resolve the matter to move forward.